M&A Deal Summary

Encore Dermatology Acquires SERNIVO Spray

On April 2, 2019, Encore Dermatology acquired medical products company SERNIVO Spray from Dr. Reddy s Laboratories

Acquisition Highlights
  • This is Encore Dermatology’s 3rd transaction in the Medical Products sector.
  • This is Encore Dermatology’s 4th transaction in the United States.
  • This is Encore Dermatology’s 3rd transaction in Pennsylvania.

M&A Deal Summary

Date 2019-04-02
Target SERNIVO Spray
Sector Medical Products
Buyer(s) Encore Dermatology
Sellers(s) Dr. Reddy s Laboratories
Deal Type Divestiture

Target

SERNIVO Spray

Malvern, Pennsylvania, United States
SERNIVO Spray is used to treat a type of skin condition (plaque psoriasis). Betamethasone reduces the swelling, itching, and redness that may occur with plaque psoriasis.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Encore Dermatology

Malvern, Pennsylvania, United States

Category Company
Founded 2014
Sector Life Science
DESCRIPTION

Encore Dermatology is a privately held fully-integrated specialty dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients. Encore Dermatology was founded in 2014 and is based in Malvern, Pennsylvania.


DEAL STATS #
Overall 4 of 4
Sector: Medical Products M&A 3 of 3
Type: Divestiture M&A Deals 4 of 4
State: Pennsylvania M&A 3 of 3
Country: United States M&A 4 of 4
Year: 2019 M&A 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-02 Trianex

Malvern, Pennsylvania, United States

Trianex is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Triamcinolone reduces the swelling, itching, and redness that can occur in these types of conditions.

Buy -

Seller(S) 1

SELLER

Dr. Reddy s Laboratories

Hyderabad, India

Category Company
Founded 1984
Sector Medical Products
Employees27,811
Revenue 325.5B INR (2025)
DESCRIPTION

Dr. Reddy’s Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. Dr. Reddy's Laboratories was founded in 1984 and is based in Hyderabad, Telangana.


DEAL STATS #
Overall 4 of 4
Sector: Medical Products M&A 3 of 3
Type: Divestiture M&A Deals 4 of 4
State: Pennsylvania M&A 3 of 3
Country: United States M&A 3 of 3
Year: 2019 M&A 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-02 Trianex

Malvern, Pennsylvania, United States

Trianex is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Triamcinolone reduces the swelling, itching, and redness that can occur in these types of conditions.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-12 Wockhardt - Select Business Divisions

Mumbai, India

Wockhardt Ltd. - Select Business Divisions comprises a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines in India and a few other international territories of Nepal, Sri Lanka, Bhutan, and the Maldives.

Buy Rs18.5B